Today: 21 March 2026
Subscribe
Browse Category

NASDAQ:RVTY 10 January 2026

Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Schrödinger will integrate Eli Lilly’s AI drug discovery platform, TuneLab, into its LiveDesign software, giving biotech teams direct access to Lilly’s predictive models. Revvity and Benchling also announced deals to offer TuneLab through their platforms. Lilly and Revvity will jointly fund access for select users, using federated learning to protect data. BigHat Biosciences will collaborate with Lilly to improve antibody developability models.
10 January 2026
····

Stock Market Today

  • 3 Reasons to Avoid Adobe Stock and a Better Pick Instead
    March 20, 2026, 7:21 PM EDT. Adobe's stock has fallen 32.4% since September 2025, dropping to $246.27 amid concerns over slowing growth. The company's annual recurring revenue (ARR) grew 13% last year, lagging the software sector. Analysts project revenue growth to slow to 8.5% over the next 12 months, signaling potential demand challenges. Adobe's operating margin, a key profitability metric including stock-based compensation (SBC) costs, has remained flat around 36.6%, raising concerns about expense management. Trading at 3.8 times forward price-to-sales, Adobe's valuation is fair but offers limited upside. Instead, investors may prefer more resilient names like companies owning brands such as Taco Bell, seen as stronger long-term plays in uncertain markets.
Go toTop